43 related articles for article (PubMed ID: 19962292)
1. Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review.
Coletti K; Wild KT; Foglia EE; Otter SC; Kirpalani H
Clin Perinatol; 2024 Mar; 51(1):253-269. PubMed ID: 38325945
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment.
Hirakawa K; Asano R; Ueda J; Aoki T; Tsuji A; Ogo T
Int J Cardiol; 2024 Jul; 406():132043. PubMed ID: 38614366
[TBL] [Abstract][Full Text] [Related]
3. Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension.
Pérez-Peñate GM; Juliá-Serdá G; Galván-Fernández H; Alemán-Segura D; León-Marrero F; Garcia-Quintana A; de Larrinoa IR; Ortega-Trujillo JR; Gómez-Sánchez MÁ
Pulm Circ; 2024 Jan; 14(1):e12344. PubMed ID: 38468631
[TBL] [Abstract][Full Text] [Related]
4. The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension.
Rockstrom MD; Jin Y; Peterson RA; Hountras P; Badesch D; Gu S; Park B; Messenger J; Forbes LM; Cornwell WK; Bull TM
Pulm Circ; 2024 Apr; 14(2):e12375. PubMed ID: 38736893
[TBL] [Abstract][Full Text] [Related]
5. [Risks of magistral preparations in pediatrics].
Rosen C; Jacqmart C; Charlier C; Beghetti M; Seghaye MC
Rev Med Liege; 2024 Feb; 79(2):104-109. PubMed ID: 38356427
[TBL] [Abstract][Full Text] [Related]
6. Role of Vasodilator Testing in Pulmonary Hypertension.
Sharma A; Obiagwu C; Mezue K; Garg A; Mukherjee D; Haythe J; Shetty V; Einstein AJ
Prog Cardiovasc Dis; 2016; 58(4):425-33. PubMed ID: 26434988
[TBL] [Abstract][Full Text] [Related]
7. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.
Maron BA; Bhatt DL; Nykiel M; Kinlay S; Waxman AB
Crit Pathw Cardiol; 2012 Mar; 11(1):40-2. PubMed ID: 22337220
[TBL] [Abstract][Full Text] [Related]
8. Under Pressure: Right Heart Catheterization and Provocative Testing for Diagnosing Pulmonary Hypertension.
Tea I; Hussain I
Methodist Debakey Cardiovasc J; 2021; 17(2):92-100. PubMed ID: 34326928
[TBL] [Abstract][Full Text] [Related]
9. Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming.
D'Alessandro A; El Kasmi KC; Plecitá-Hlavatá L; Ježek P; Li M; Zhang H; Gupte SA; Stenmark KR
Antioxid Redox Signal; 2018 Jan; 28(3):230-250. PubMed ID: 28637353
[TBL] [Abstract][Full Text] [Related]
10. Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.
Del Cerro MJ; Moledina S; Haworth SG; Ivy D; Al Dabbagh M; Banjar H; Diaz G; Heath-Freudenthal A; Galal AN; Humpl T; Kulkarni S; Lopes A; Mocumbi AO; Puri GD; Rossouw B; Harikrishnan S; Saxena A; Udo P; Caicedo L; Tamimi O; Adatia I
Pulm Circ; 2016 Mar; 6(1):118-25. PubMed ID: 27076908
[TBL] [Abstract][Full Text] [Related]
11. Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.
Sandqvist A; Henrohn D; Egeröd H; Hedeland M; Wernroth L; Bondesson U; Schneede J; Wikström G
Eur J Clin Pharmacol; 2015 Oct; 71(10):1165-73. PubMed ID: 26242227
[TBL] [Abstract][Full Text] [Related]
12. A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study.
Bazl R; Ganjali MR; Saboury AA; Foroumadi A; Nourozi P; Amanlou M
Daru; 2012 Oct; 20(1):64. PubMed ID: 23351306
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.
Price LC; Wort SJ; Finney SJ; Marino PS; Brett SJ
Crit Care; 2010; 14(5):R169. PubMed ID: 20858239
[TBL] [Abstract][Full Text] [Related]
14. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide.
Oliveira EC; Ribeiro AL; Amaral CF
Respir Med; 2010 Apr; 104(4):606-11. PubMed ID: 19962292
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
Santini F; Casali G; Franchi G; Auriemma S; Lusini M; Barozzi L; Favaro A; Messina A; Mazzucco A
Int J Cardiol; 2005 Aug; 103(2):156-63. PubMed ID: 16080974
[TBL] [Abstract][Full Text] [Related]
17. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery.
Schmid ER; Bürki C; Engel MH; Schmidlin D; Tornic M; Seifert B
Anesth Analg; 1999 Nov; 89(5):1108-15. PubMed ID: 10553820
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
